Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 10 | 2023 | 103 | 1.670 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 12 | 2023 | 23 | 1.410 |
Why?
|
| Immunosuppressive Agents | 10 | 2023 | 136 | 0.850 |
Why?
|
| Natalizumab | 3 | 2019 | 21 | 0.690 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2019 | 113 | 0.660 |
Why?
|
| Immunologic Factors | 2 | 2019 | 34 | 0.650 |
Why?
|
| Filgrastim | 1 | 2019 | 6 | 0.650 |
Why?
|
| JC Virus | 1 | 2019 | 98 | 0.590 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2020 | 93 | 0.540 |
Why?
|
| Immunoglobulin G | 6 | 2020 | 95 | 0.520 |
Why?
|
| Disease Progression | 4 | 2020 | 718 | 0.310 |
Why?
|
| Interferon Regulatory Factor-1 | 3 | 2011 | 10 | 0.270 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2009 | 115 | 0.240 |
Why?
|
| Aquaporin 4 | 2 | 2014 | 7 | 0.220 |
Why?
|
| Neuromyelitis Optica | 2 | 2014 | 7 | 0.220 |
Why?
|
| Central Nervous System Diseases | 1 | 2023 | 18 | 0.210 |
Why?
|
| Adult | 14 | 2020 | 8021 | 0.210 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2019 | 1181 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 4 | 2011 | 201 | 0.200 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 3 | 2011 | 68 | 0.190 |
Why?
|
| Female | 18 | 2020 | 15534 | 0.180 |
Why?
|
| Humans | 23 | 2023 | 28054 | 0.180 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2020 | 8 | 0.180 |
Why?
|
| Male | 15 | 2020 | 15143 | 0.160 |
Why?
|
| Brain | 3 | 2019 | 1690 | 0.140 |
Why?
|
| Treatment Outcome | 8 | 2023 | 3530 | 0.140 |
Why?
|
| Retrospective Studies | 4 | 2023 | 3524 | 0.140 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2016 | 13 | 0.130 |
Why?
|
| Middle Aged | 13 | 2016 | 9186 | 0.120 |
Why?
|
| Muscular Diseases | 1 | 2014 | 18 | 0.120 |
Why?
|
| Spinal Cord Compression | 1 | 2014 | 24 | 0.120 |
Why?
|
| Follow-Up Studies | 5 | 2023 | 1809 | 0.110 |
Why?
|
| Cladribine | 2 | 2023 | 2 | 0.110 |
Why?
|
| Tablets | 2 | 2023 | 6 | 0.110 |
Why?
|
| Decompression, Surgical | 1 | 2014 | 130 | 0.100 |
Why?
|
| Aquaporins | 1 | 2012 | 7 | 0.100 |
Why?
|
| Escherichia coli Proteins | 1 | 2012 | 11 | 0.100 |
Why?
|
| Demyelinating Diseases | 1 | 2011 | 15 | 0.090 |
Why?
|
| Double-Blind Method | 4 | 2014 | 423 | 0.090 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2011 | 2 | 0.090 |
Why?
|
| Immunomodulation | 1 | 2011 | 7 | 0.090 |
Why?
|
| Oligodendroglia | 1 | 2011 | 37 | 0.090 |
Why?
|
| Neuroglia | 1 | 2011 | 49 | 0.090 |
Why?
|
| Cervical Vertebrae | 1 | 2014 | 295 | 0.090 |
Why?
|
| Young Adult | 5 | 2020 | 2043 | 0.090 |
Why?
|
| DNA | 1 | 2010 | 103 | 0.080 |
Why?
|
| Thiazolidinediones | 1 | 2009 | 9 | 0.080 |
Why?
|
| Recurrence | 2 | 2023 | 318 | 0.080 |
Why?
|
| Disability Evaluation | 3 | 2009 | 290 | 0.080 |
Why?
|
| Neuroprotective Agents | 1 | 2009 | 55 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2011 | 455 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2010 | 158 | 0.080 |
Why?
|
| Cyclophosphamide | 2 | 2023 | 49 | 0.070 |
Why?
|
| Central Nervous System | 2 | 2023 | 57 | 0.070 |
Why?
|
| Animals | 6 | 2012 | 3824 | 0.070 |
Why?
|
| Transplantation Conditioning | 1 | 2006 | 41 | 0.070 |
Why?
|
| Mice | 4 | 2012 | 1494 | 0.070 |
Why?
|
| Autoimmune Diseases | 1 | 2006 | 47 | 0.060 |
Why?
|
| Injections, Subcutaneous | 2 | 2016 | 25 | 0.060 |
Why?
|
| Europe | 2 | 2014 | 65 | 0.050 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2003 | 2 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 351 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 206 | 0.050 |
Why?
|
| Adolescent | 3 | 2013 | 2289 | 0.050 |
Why?
|
| Rabbits | 2 | 2012 | 193 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2011 | 116 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2012 | 539 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2011 | 325 | 0.040 |
Why?
|
| Time Factors | 2 | 2014 | 1485 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 1366 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2011 | 449 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2009 | 176 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2016 | 1882 | 0.040 |
Why?
|
| Nasopharyngitis | 1 | 2016 | 1 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 8 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2016 | 10 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2016 | 24 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2016 | 14 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2016 | 15 | 0.030 |
Why?
|
| Safety | 1 | 2016 | 44 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2016 | 33 | 0.030 |
Why?
|
| Colitis, Ulcerative | 1 | 2016 | 64 | 0.030 |
Why?
|
| Pneumonia | 1 | 2016 | 77 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 2014 | 21 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 178 | 0.030 |
Why?
|
| Structural Homology, Protein | 1 | 2012 | 5 | 0.030 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2012 | 9 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 165 | 0.030 |
Why?
|
| Cross Reactions | 1 | 2012 | 12 | 0.030 |
Why?
|
| Reference Values | 1 | 2013 | 201 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2012 | 69 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 154 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 196 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 213 | 0.020 |
Why?
|
| Electrophoresis | 1 | 2011 | 5 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 138 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 57 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 233 | 0.020 |
Why?
|
| Expert Testimony | 1 | 2010 | 14 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 366 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 664 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 90 | 0.020 |
Why?
|
| Plasma | 1 | 2010 | 19 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2010 | 37 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 60 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 57 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2010 | 58 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 99 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2010 | 81 | 0.020 |
Why?
|
| Inflammation | 1 | 2011 | 287 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 83 | 0.020 |
Why?
|
| Antilymphocyte Serum | 1 | 2009 | 3 | 0.020 |
Why?
|
| Alemtuzumab | 1 | 2009 | 5 | 0.020 |
Why?
|
| Gadolinium | 1 | 2009 | 8 | 0.020 |
Why?
|
| Antirheumatic Agents | 1 | 2010 | 86 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2010 | 114 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2009 | 13 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 69 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2010 | 180 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2009 | 167 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 492 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 511 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2009 | 268 | 0.020 |
Why?
|
| Quality of Life | 1 | 2013 | 655 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 633 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2009 | 432 | 0.020 |
Why?
|
| Spinal Fusion | 1 | 2014 | 474 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2010 | 263 | 0.020 |
Why?
|
| Biomarkers | 1 | 2010 | 581 | 0.020 |
Why?
|
| Factor VIII | 1 | 2006 | 32 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 990 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2003 | 11 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2003 | 162 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 306 | 0.010 |
Why?
|
| Aged | 1 | 2014 | 9222 | 0.010 |
Why?
|